Insider Selling: Vericel (NASDAQ:VCEL) Insider Sells $220,050.00 in Stock

Vericel Corporation (NASDAQ:VCEL) insider Jonathan Siegal sold 4,500 shares of the firm’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $48.90, for a total value of $220,050.00. Following the sale, the insider directly owned 1,078 shares in the company, valued at $52,714.20. The trade was a 80.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Jonathan Siegal also recently made the following trade(s):

• On Friday, June 26th, Jonathan Siegal sold 2,732 shares of Vericel stock. The shares were sold at an average price of $44.90, for a total value of $122,666.80.

Vericel Stock Performance

NASDAQ:VCEL opened at $45.96 on Monday. Vericel Corporation has a 1 year low of $28.95 and a 1 year high of $49.32. The stock has a 50-day moving average price of $41.95 and a two-hundred day moving average price of $37.39. The stock has a market cap of $2.35 billion, a price-to-earnings ratio of 97.79 and a beta of 1.06.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, July 30th. The biotechnology company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. Vericel had a return on equity of 6.91% and a net margin of 7.91%.The company had revenue of $77.46 million for the quarter, compared to analyst estimates of $72.70 million. During the same quarter last year, the firm posted ($0.01) earnings per share. Vericel’s revenue was up 22.5% compared to the same quarter last year. Sell-side analysts forecast that Vericel Corporation will post 0.49 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Canaccord Genuity Group set a $60.00 price target on shares of Vericel in a research note on Thursday. Wall Street Zen raised shares of Vericel from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. TD Cowen raised their price objective on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Friday. Truist Financial reaffirmed a “buy” rating and issued a $58.00 price objective (up from $54.00) on shares of Vericel in a research report on Friday. Finally, Weiss Ratings raised shares of Vericel from a “sell (d+)” rating to a “hold (c)” rating in a research note on Friday. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Vericel currently has an average rating of “Moderate Buy” and an average target price of $58.40.

More Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported second-quarter revenue of $77.5 million, up 22% year over year and above the $72.7 million consensus estimate. Earnings were $0.04 per share, beating expectations for a $0.04 loss, while net income reached $2.2 million and free cash flow was $14.3 million. Vericel Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $330 million-$340 million, a range that brackets or modestly exceeds the $331.9 million analyst consensus. MACI revenue growth of 23% was a key contributor to the quarterly performance. Vericel Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: The board authorized a $200 million share-repurchase program, which could support earnings per share and signal confidence in Vericel’s cash-generation outlook. Share Repurchase Program Announcement
• Positive Sentiment: Truist reaffirmed its Buy rating and increased its price target to $58 from $54. HC Wainwright also reaffirmed a Buy rating, reinforcing the favorable analyst view. Truist Financial Analyst Rating HC Wainwright Analyst Rating
• Neutral Sentiment: The earnings-call transcript and presentation provide additional operating details but do not indicate a separate material catalyst beyond the reported results and guidance. Q2 2026 Earnings Presentation
• Neutral Sentiment: Analyst sentiment is not unanimous, and Vericel trades at a high earnings multiple, leaving the shares sensitive to any slowdown in growth or weaker-than-expected future results. Conflicting Analyst Sentiment

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in VCEL. AQR Capital Management LLC acquired a new stake in Vericel in the 1st quarter valued at $242,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Vericel by 6.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,445 shares of the biotechnology company’s stock worth $1,403,000 after buying an additional 1,847 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Vericel by 13.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 371,486 shares of the biotechnology company’s stock worth $16,576,000 after buying an additional 44,333 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Vericel by 9.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,028 shares of the biotechnology company’s stock valued at $5,490,000 after acquiring an additional 10,191 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its holdings in shares of Vericel by 5.1% in the 2nd quarter. Qube Research & Technologies Ltd now owns 277,253 shares of the biotechnology company’s stock valued at $11,797,000 after acquiring an additional 13,422 shares in the last quarter.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.